Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

METiS and WestVac Biopharma Forge AI Partnership to Develop Personalized mRNA Cancer Vaccines

Fineline Cube Aug 21, 2026
Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Policy / Regulatory

China NHC Mandates Priority Use of Essential Medicines as 2026 National List Takes Effect

Fineline Cube Aug 21, 2026
Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Fineline Cube Aug 24, 2026
Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Fineline Cube Aug 24, 2026
Company Deals

Bio‑Sincerity Secures XPO1 Inhibitor Deal for BIOS‑0629, Aims at Solid‑Tumor Expansion

Fineline Cube Nov 13, 2025

Hangzhou Bio‑Sincerity Pharma‑Tech Co., Ltd. (SHE: 301096) announced that the company has signed a Technology...

Company

Bayer Reports Stable Q3 2025 Sales, Highlights Strong Nubeqa and Kerendia Growth

Fineline Cube Nov 13, 2025

Bayer AG (ETR: BAYN) announced on November 12 2025 that its third‑quarter 2025 (2025Q3) performance matched prior‑year...

Policy / Regulatory

FDA Announces New ‘Plausible‑Mechanism’ Pathway to Rapid Approvals for Rare Disease Treatments

Fineline Cube Nov 13, 2025

The U.S. Food and Drug Administration (FDA) announced on Wednesday a landmark regulatory shift that could...

Company Deals

Complete Genomics and SOPHiA Genetics Join Forces to Deliver End‑to‑End Oncology Validation on MGI’s T1+ Sequencing Platform

Fineline Cube Nov 13, 2025

Complete Genomics, the U.S. subsidiary of MGI Technologies (SHA: 688114), announced today a strategic collaboration...

Company Deals

Degron Therapeutics, MSD R&D, and the Next Generation of Molecular Glue Degraders

Fineline Cube Nov 13, 2025

Degron Therapeutics, a China‑based pioneer in protein‑degradation therapies, today announced the signing of a Letter...

Company Deals

Adicon Holdings, Crown Bioscience, and Global Lab Services Forge New Integrated Platform for Oncology Translational Research

Fineline Cube Nov 13, 2025

Adicon Holdings Ltd. (HKG: 9860), a leading independent clinic laboratory (ICL) service provider in China,...

Company Deals

AbbVie to End 11‑Year R&D Alliance with Alphabet‑Owned Calico Labs

Fineline Cube Nov 13, 2025

AbbVie Inc. (NYSE: ABBV) announced today that it will terminate its long‑standing collaboration agreement with...

Company Deals

ChengDa Biotechnology, IMCAS, and Beijing Key Laboratory for Synthetic Immunology Forge New Frontiers in Vaccine Manufacturing

Fineline Cube Nov 12, 2025

Liaoning ChengDa Biotechnology Co., Ltd. and the Institute of Microbiology, Chinese Academy of Sciences (IMCAS)...

Company Deals

Sun‑Novo, Byterna, and CAR‑T/CircRNA Collaboration Propel In‑Vivo Gene‑Therapy Frontiers

Fineline Cube Nov 12, 2025

Beijing Sun‑Novo Pharmaceutical Research Co., Ltd. today disclosed a strategic capital injection of RMB 15 million into...

Company Deals

Suzhou Forlong Biotech, Shanghai Henlius, and Engineered Cytokine Immunotherapy Collaboration Announced

Fineline Cube Nov 12, 2025

Suzhou Forlong Biotechnology Co., Ltd. today revealed a strategic partnership with Shanghai Henlius Biotech, Inc....

Company Deals Hospital

GemPharmatech, Memorial Sloan Kettering, and NeoMab Platform Accelerate Discovery of Fully Human Therapeutic Antibodies

Fineline Cube Nov 12, 2025

GemPharmatech Inc., (SHA: 688046) a global leader in pre‑clinical research solutions and genetically‑engineered mouse models,...

Company Deals

Jinling Pharmaceutical, Nanjing Gulou Hospital, and CD16a Tech‑Transfer Deal Bolsters NK‑Cell Oncology

Fineline Cube Nov 12, 2025

Jinling Pharmaceutical Co., Ltd. (SHE: 000919) today announced a strategic technology transfer agreement with Nanjing...

Company Deals

Jacobio Pharma, Oceanpine Capital and Partner Acquire Majority of Jacoray, Fuelling Early‑Stage Cardio‑Oncology R&D

Fineline Cube Nov 12, 2025

Jacobio Pharma Ltd. (HKG: 1167) announced today that its subsidiary Beijing Jacobio Pharmaceuticals Co., Ltd....

Company Deals

Walvax Biotechnology & Pharmaniaga Lifescience Forge Malaysia Partnership for PCV‑13 Production and Distribution

Fineline Cube Nov 12, 2025

Walvax Biotechnology Co., Ltd. and Pharmaniaga Lifescience Sdn. Bhd. (wholly‑owned by Pharmaniaga Berhad) today announced a...

Company Deals

Shandong Buchang’s Luzhou Unit Moves to Secure Exclusive Distribution of Epo‑IgG Fusion in Vietnam

Fineline Cube Nov 12, 2025

Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today that its subsidiary Luzhou Buchang will enter...

Others

AnkeBio and PersonGen Ink Capital‑Increase Deal, Secure Exclusive Greater‑China Agency for PA3‑17 CAR‑T Therapy

Fineline Cube Nov 12, 2025

Anhui Anke Biotechnology (Group) Co., Ltd. and PersonGen BioTherapeutics (Suzhou) Co., Ltd. (PersonGen) announced today...

Company Drug

Chongqing Precision Biotech Wins NMPA Approval for pCAR‑19B – China’s First Humanised CD19 CAR‑T Therapy for Pediatric B‑ALL

Fineline Cube Nov 12, 2025

Chongqing Precision Biotech Co., Ltd. announced that its pCAR‑19B cell‑based product has received National Medical...

Company Deals Drug

Laekna and Qilu Pharma Sign Exclusive China License for AKT Inhibitor LAE002 (Afuresertib)

Fineline Cube Nov 12, 2025

Sino-US biotech Laekna Therapeutics (HKG: 2105) and Qilu Pharmaceutical Co., Ltd. announced today an exclusive...

Company Drug

NMPA Grants Marketing Authorisation to Hefei Amvite’s Memantine Hydrochloride ODT for Alzheimer’s Disease

Fineline Cube Nov 12, 2025

The National Medical Products Administration (NMPA) has approved Memantine Hydrochloride Orally Disintegrating Tablets (ODT) produced...

Company Drug

Shanghai Henlius Biotech Secures UK MHRA Approval for Denosumab Biosimilars BILDYOS & BILPREVDA

Fineline Cube Nov 12, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the United Kingdom’s Medicines and Healthcare Products...

Posts pagination

1 … 125 126 127 … 711

Recent updates

  • Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval
  • Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia
  • ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.
  • North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate
  • Simcere H1 Earnings Surge as Neuroscience Revenue Jumps 60.9% and Profit Rises 37.9%
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs Files NDA for Opamtistomig in EP-NEC — World’s First 4-1BB Bispecific Nears Potential First Approval

Company Drug

Yipinhong Wins NMPA Clinical Trial Approval for Category 1 URAT1 Inhibitor APH03867 in Gout and Hyperuricemia

Company Drug

ImmuneOnco’s IMM0306 Wins FDA IND Clearance for SLE — World’s First CD47/CD20 Bispecific in Clinic Enters U.S.

Company Drug

North China Pharma Wins NMPA Clinical Trial Approval for World-First Hexavalent Norovirus Vaccine Candidate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.